Fintel reports that on November 18, 2024, BTIG initiated coverage of VYNE Therapeutics (NasdaqCM:VYNE) with a Buy ...

BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target VYNE is pioneering the development of BET inhibitors in large inflammation and immunology, or I&I, ...

BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target Don't Miss our Black Friday Offers: Discover the latest stocks recommended by top Wall Street analysts, all in ...

The trial was initiated in June 2024 and VYNE expects to report top-line results from the 24-week double-blind portion of the trial in mid-2025. The Phase 2b trial (NCT06493578) is a randomized ...

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -20.83% and 10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

MARTINIS AND MISTLETOEThe Palace Theater in Waterbury is bringing back "Martinis & Mistletoe" on Dec. 5 at 6 p.m.The festive ...

Tarabut, the MENA region's leading, regulated open banking platform, and Geidea, Saudi Arabia's leading payments solutions provider, have entered a strategic partnership to explore and potentially ...

NASDAQ:VYNE opened at $3.16 on Friday. The firm has a market capitalization of $46.61 million, a PE ratio of -1.22 and a beta of 1.32. The stock’s fifty day moving average is $2.17 and its 200 ...

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025 Reported positive first-in-human Phase 1a SAD data ...

Earlier this year Tarabut acquired London-based Vyne, a real-time account-to-account (A2A) payments platform for online ...

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $1.85 per share a year ago.